Posted on 9/18/17
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies."Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies . . .
Posted on 9/18/17
Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
After winning Food and Drug Administration (FDA) approval for use in castration-resistant metastatic prostate cancer in 2012, Pfizer's (NYSE:PFE) Xtandi quickly gained ground on Johnson & . . .
Posted on 9/18/17
The Smartest Move Johnson & Johnson Has Made All Year
Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is what you might call a stalwart in the portfolios of risk-averse, income-seeking long-term investors. It's about as rock-solid as . . .
Posted on 9/18/17
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE:JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings . . .
Posted on 9/18/17
Don't Make This Huge Mistake With Celgene
Several years ago, I started to look seriously at investing in Celgene (NASDAQ:CELG) stock. Someone I knew told me that I probably shouldn't get too excited . . .
Posted on 9/15/17
Celgene (CELG) Presents at Bank of America Merrill Lynch Global Healthcare Broker Conference (Transcript)
Celgene Corporation (NASDAQ:CELG)Bank of America Merrill Lynch Global Healthcare ConferenceSeptember 14, 2017, 11:10 AM ETExecutivesPeter Kellogg - CFOAnalystsYing Huang - Bank of America Merrill LynchYing HuangOkay. . . .
Posted on 9/15/17
Teva Looks to Hit Insys Where It Hurts
Insys (INSY) is now battling what could be its biggest threat and a challenge that may have profoundly negative consequences for the company going forward. INSY . . .
Posted on 9/15/17
Teva Pharmaceutical Finally Has Some Positive News
Teva Pharmaceutical (NYSE:TEVA) finally delivered on a good news show, as investors welcomed the positive news flow. Shares jumped a quarter from their lows on the . . .
Posted on 9/15/17
Teva's New CEO Is A Blessing
Teva Pharmaceutical Industries Ltd. (TEVA) has finally appointed a new CEO named Kare Schultz. Shareholders seemed desperate enough that simply appointing any CEO would probably have . . .
Posted on 9/14/17
MD Anderson and Daiichi Sankyo Enter Research Collaboration
The University of TexasMD Anderson Cancer Center and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a multi-year collaboration focused on accelerating the development of . . .
Posted on 9/14/17
SEI Partners with Art Ability at Bryn Mawr Rehab Hospital
SEI (NASDAQ: SEIC) today announced a partnership with Art Ability, an organization which serves as a unique and accessible venue for artists with disabilities, to display . . .
Posted on 9/14/17
Trinitas Regional Medical Center Names its New $18.7 Million Emergency Department After Renowned Hospital Executive Gary S. Horan
To honor his five decades of healthcare leadership in both New York and New Jersey, Trinitas Regional Medical Center today named its new $18.7 million Emergency . . .
Posted on 9/14/17
TransCelerate BioPharma Grows Industry Collaboration
PHILADELPHIA--(BUSINESS WIRE)--TransCelerate BioPharma Inc. announces the addition of Novartis (NYSE: NVS) to the biopharmaceutical non-profit organization, growing the consortium to 19 biopharmaceutical companies. In addition, TransCelerate . . .
Posted on 9/14/17
Johnson & Johnson's (JNJ) Management Presents at Morgan Stanley Healthcare Conference Call (Transcript)
Johnson & Johnson (NYSE:JNJ)Morgan Stanley Healthcare ConferenceSeptember 13, 2017 02:10 PM ETExecutivesDominic Caruso - Chief Financial OfficerAnalystsDavid Lewis - Morgan StanleyDavid LewisThanks for joining us here. . . .
Posted on 9/14/17
Teva: Avoid
Source: TradingviewInvestment ThesisTeva Pharmaceutical (TEVA) recently announced that it has entered into a definitive agreement to sell its Paragard contraceptive device to CooperSurgical for $1.1 billion . . .
Posted on 9/14/17
Johnson & Johnson's Management Presents at Morgan Stanley Healthcare Conference Call
Thanks for joining us here. My name is David Lewis, Medical Device Analyst from Morgan Stanley. Thanks for joining us here to round out medical device . . .
Posted on 9/14/17
Kyowa Hakko Kirin Joins Certara’s Simcyp Consortium
PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global leader in model-informed drug development and regulatory science, today announced that Kyowa Hakko Kirin Co., Ltd. has joined the Simcyp Consortium . . .
Posted on 9/13/17
Teva: Caution Is Warranted
In early August, I wrote an article recommending Mylan (MYL) instead of Teva Pharmaceutical Industries (TEVA) for those who would like to play the possible recovery . . .
Posted on 9/13/17
Lonnie Zeltzer, MD, Joins F4CP in Recommending Drug-Free Chiropractic Care for Pediatric Pain Management
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--The Foundation for Chiropractic Progress (F4CP), a leading voice of the chiropractic profession and sponsor of September Drug-Free Pain Management Awareness Month, emphasizes . . .
Posted on 9/13/17
Pager and Horizon Blue Cross Blue Shield of New Jersey Collaborate to Improve Access to Care
NEW YORK & NEWARK, N.J.--(BUSINESS WIRE)--Pager and Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ), the oldest and largest health insurer in New Jersey . . .
Posted on 9/12/17
Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001
BEDMINSTER, N.J., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, . . .
Posted on 9/12/17
Merck's (MRK) Management Presents at Morgan Stanley Healthcare Conference - Transcript
Merck & Co., Inc. (NYSE:MRK)Morgan Stanley Healthcare ConferenceSeptember 12, 2017, 02:50 PM ETExecutivesKen Frazier - Chief Executive OfficerRoger Perlmutter - Executive Vice President and President, Merck . . .
Posted on 9/12/17
Allergan's Patent Loophole Could Be a Huge Gift for Pfizer
The tribe has spoken.On Friday, Allergan (NYSE:AGN) announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. Both parties . . .
Posted on 9/12/17
Teva: The Turning Point
In our dividend investment strategies, we generally look for high-quality companies with sustainable payouts that are being neglected or shunned by the majority of the market. . . .
Posted on 9/12/17
Celgene Offers High Growth At An Inexpensive Price
Six of Celgene's (CELG) clinical trials were put on hold on Thursday, but the company's growth will remain outstanding for the coming years. The strong growth . . .

